Xin Lang Cai Jing·2026-03-10 07:08Core Viewpoint - Xinhua Pharmaceutical has shown a slight increase in stock price and has a significant market presence in the production of analgesic and antipyretic medications, with a focus on flu treatment and other therapeutic areas [1][11]. Group 1: Company Overview - Xinhua Pharmaceutical is a major global producer of analgesic medications, including Ibuprofen and Aspirin, widely used for flu-related symptoms [2][12]. - The company also produces medications for liver disease and has a range of products for treating Helicobacter pylori infections [3][13]. - Xinhua Pharmaceutical has established online sales channels and partnerships with hospitals, clinics, and pharmacies [4][14]. - The company signed a framework cooperation agreement with Alibaba Group in March 2018 to collaborate in various fields, including B2B business and cloud computing [4][14]. - As of September 30, 2025, Xinhua Pharmaceutical reported a revenue of 6.763 billion yuan, a year-on-year increase of 0.42%, while net profit decreased by 25.53% to 256 million yuan [9][19]. Group 2: Financial Analysis - The stock's average trading cost is 16.26 yuan, with the current price near a support level of 15.44 yuan [7][18]. - The main capital inflow today was 1.0508 million yuan, accounting for 0.02% of the total, with a ranking of 55 out of 158 in the industry [4][15]. - The distribution of shares is very dispersed, with the main capital accounting for only 7.4% of the total transaction amount [6][17]. - The number of shareholders decreased by 7.60% to 70,700 as of September 30, 2025 [9][20].